127 related articles for article (PubMed ID: 38324766)
1. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
J Infect Dis; 2024 Feb; ():. PubMed ID: 38324766
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
3. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
4. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
5. Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.
Wang HY; Li L; Nelson CS; Barfield R; Valencia S; Chan C; Muramatsu H; Lin PJC; Pardi N; An Z; Weissman D; Permar SR
NPJ Vaccines; 2024 Feb; 9(1):38. PubMed ID: 38378950
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
[TBL] [Abstract][Full Text] [Related]
7. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
8. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
9. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
[TBL] [Abstract][Full Text] [Related]
10. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.
Li F; Freed DC; Tang A; Rustandi RR; Troutman MC; Espeseth AS; Zhang N; An Z; McVoy M; Zhu H; Ha S; Wang D; Adler SP; Fu TM
NPJ Vaccines; 2017; 2():36. PubMed ID: 29263890
[TBL] [Abstract][Full Text] [Related]
11. Human Cytomegalovirus (HCMV)-Specific Antibody Response and Development of Antibody-Dependent Cellular Cytotoxicity Against HCMV After Lung Transplantation.
Vietzen H; Görzer I; Honsig C; Jaksch P; Puchhammer-Stöckl E
J Infect Dis; 2020 Jul; 222(3):417-427. PubMed ID: 32157310
[TBL] [Abstract][Full Text] [Related]
12. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
13. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
14. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
15. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
16. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
17. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
18. A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
Gomes AC; Baraniak IA; McIntosh MR; Sodi I; Langstone T; Siddiqui S; Atkinson C; McLean GR; Griffiths PD; Reeves MB
J Gen Virol; 2023 Jun; 104(6):. PubMed ID: 37310000
[TBL] [Abstract][Full Text] [Related]
19. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
Wu K; Hou YJ; Makrinos D; Liu R; Zhu A; Koch M; Yu W-H; Paila YD; Chandramouli S; Panther L; Henry C; DiPiazza A; Carfi A
J Virol; 2024 Apr; 98(4):e0160323. PubMed ID: 38526054
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus.
Harnois MJ; Dennis M; Stöhr D; Valencia SM; Rodgers N; Semmes EC; Webster HS; Jenks JA; Barfield R; Pollara J; Chan C; Sinzger C; Permar SR
J Infect Dis; 2022 Nov; 226(9):1667-1677. PubMed ID: 35970817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
